Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07682311 · ClinicalTrials.gov registry record · NA
Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator
A NA study, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07682311 is a NA study that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants.
The verdict
NCT07682311, a NA study, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Parkinson's disease (PD) affects \~1% of people over 60 years old, is highly disabling and represents a large economic burden. While dopaminergic medications effectively treat motor symptoms early in the disease, most patients develop complications, including motor fluctuations and dyskinesias, which can be partially managed by deep brain stimulation (DBS). This surgical therapy consists of delivering continuous electrical stimulation through electrodes permanently implanted in basal ganglia nuclei, with a pulse generator and battery unit implanted in the chest. However, conventional DBS therapy is delivered with constant stimulation parameters, referred to as constant deep brain stimulation (cDBS), that are unresponsive to patient activities or to variations in the severity of symptoms during daily life. This leaves many patients under- or over-stimulated during parts of the day. To address the shortcomings of cDBS, adaptive DBS (aDBS) uses real-time detection of neural signals to automatically adjust stimulation amplitude or other parameters in response to patients' dynamic clinical needs. aDBS was approved by the U.S. Food and Drugs Administration (FDA) for clinical treatment of PD in the Percept PC and RC (Medtronic) device in February 2025. Fully leveraging this therapy in the real world is limited by technical challenges, in particular the fact that: while the investigators developed a consistent pipeline for implementing aDBS, there were several critical control parameters that strongly influenced algorithm performance and required prolonged trial-and-error based testing, to achieve successful control. In this new study, the investigators seek to significantly extend this work and address the major barriers to widespread, easy adoption of aDBS by groups without specialized knowledge of neurophysiology or feedback control. Here the investigators aim to test an automated, data-driven pipeline for the recommendation of the adaptive control parameters.
Interventions
- DEVICE Medtronic Percept Deep Brain Stimulation (cDBS)
- DEVICE Medtronic Percept Deep Brain Stimulation (adaptive DBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06 |
| Est. Completion | 2032-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07682311
The ClinicalTrials.gov registry entry for NCT07682311 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medtronic Percept Deep Brain Stimulation (cDBS) is the first listed.
NCT07682311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07682311 about?
NCT07682311 is a clinical study titled "Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator". Parkinson's disease (PD) affects \~1% of people over 60 years old, is highly disabling and represents a large economic burden. While dopaminergic medications effectively treat motor symptoms early in the disease, most patients develop complications, including motor fluctuations and dyskinesias, whic...
What is the current status of trial NCT07682311?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-06. Estimated completion is 2032-05.
What interventions are being tested in trial NCT07682311?
The interventions under investigation include: Medtronic Percept Deep Brain Stimulation (cDBS) (DEVICE), Medtronic Percept Deep Brain Stimulation (adaptive DBS) (DEVICE).
Who is sponsoring clinical trial NCT07682311?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.